Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.

Alimbetov D, Askarova S, Umbayev B, Davis T, Kipling D.

Int J Mol Sci. 2018 Jun 6;19(6). pii: E1690. doi: 10.3390/ijms19061690. Review.

2.

Elevated levels of the small GTPase Cdc42 induces senescence in male rat mesenchymal stem cells.

Umbayev B, Masoud AR, Tsoy A, Alimbetov D, Olzhayev F, Shramko A, Kaiyrlykyzy A, Safarova Y, Davis T, Askarova S.

Biogerontology. 2018 Jul;19(3-4):287-301. doi: 10.1007/s10522-018-9757-5. Epub 2018 May 26.

PMID:
29804242
3.

Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts.

Davis T, Brook AJ, Rokicki MJ, Bagley MC, Kipling D.

Pharmaceuticals (Basel). 2016 Apr 28;9(2). pii: E23. doi: 10.3390/ph9020023.

4.

The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells.

Bagley MC, Dwyer JE, Baashen M, Dix MC, Murziani PG, Rokicki MJ, Kipling D, Davis T.

Org Biomol Chem. 2016 Jan 21;14(3):947-56. doi: 10.1039/c5ob02229k. Epub 2015 Nov 27.

PMID:
26611938
5.

Suppression of the senescence-associated secretory phenotype (SASP) in human fibroblasts using small molecule inhibitors of p38 MAP kinase and MK2.

Alimbetov D, Davis T, Brook AJ, Cox LS, Faragher RG, Nurgozhin T, Zhumadilov Z, Kipling D.

Biogerontology. 2016 Apr;17(2):305-15. doi: 10.1007/s10522-015-9610-z. Epub 2015 Sep 23.

6.

Microwave-Assisted Synthesis of a MK2 Inhibitor by Suzuki-Miyaura Coupling for Study in Werner Syndrome Cells.

Bagley MC, Baashen M, Chuckowree I, Dwyer JE, Kipling D, Davis T.

Pharmaceuticals (Basel). 2015 Jun 3;8(2):257-76. doi: 10.3390/ph8020257.

7.

Nijmegen breakage syndrome fibroblasts expressing the C-terminal truncated NBN(p70) protein undergo p38/MK2-dependent premature senescence.

Davis T, Tivey HS, Brook AJ, Kipling D.

Biogerontology. 2015 Feb;16(1):43-51. doi: 10.1007/s10522-014-9530-3. Epub 2014 Sep 12.

8.

Small molecule inhibition of p38 MAP kinase extends the replicative life span of human ATR-Seckel syndrome fibroblasts.

Tivey HS, Rokicki MJ, Barnacle JR, Rogers MJ, Bagley MC, Kipling D, Davis T.

J Gerontol A Biol Sci Med Sci. 2013 Sep;68(9):1001-9. doi: 10.1093/gerona/gls336. Epub 2013 Feb 11.

9.

The effect of small-molecule inhibition of MAPKAPK2 on cell ageing phenotypes of fibroblasts from human Werner syndrome.

Davis T, Rokicki MJ, Bagley MC, Kipling D.

Chem Cent J. 2013 Jan 29;7(1):18. doi: 10.1186/1752-153X-7-18.

10.

p38 (MAPK) stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes.

Tivey HS, Brook AJ, Rokicki MJ, Kipling D, Davis T.

Biogerontology. 2013 Feb;14(1):47-62. doi: 10.1007/s10522-012-9407-2. Epub 2012 Oct 31.

11.

Activation of p38 MAP kinase and stress signalling in fibroblasts from the progeroid Rothmund-Thomson syndrome.

Davis T, Tivey HS, Brook AJ, Grimstead JW, Rokicki MJ, Kipling D.

Age (Dordr). 2013 Oct;35(5):1767-83. doi: 10.1007/s11357-012-9476-9. Epub 2012 Sep 22.

12.

Investigating the role of c-Jun N-terminal kinases in the proliferation of Werner syndrome fibroblasts using diaminopyridine inhibitors.

Davis T, Dix MC, Rokicki MJ, Brook AJ, Widdowson CS, Kipling D, Bagley MC.

Chem Cent J. 2011 Dec 8;5(1):83. doi: 10.1186/1752-153X-5-83.

13.

Microwave-assisted synthesis of a pyrazolyl ketone library for evaluation as p38 MAPK inhibitors in Werner syndrome cells.

Bagley MC, Davis T, Dix MC, Murziani PG, Rokicki MJ, Kipling D.

Future Med Chem. 2010 Feb;2(2):203-13. doi: 10.4155/fmc.09.160.

PMID:
21426187
14.

Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome.

Bagley MC, Davis T, Rokicki MJ, Widdowson CS, Kipling D.

Future Med Chem. 2010 Feb;2(2):193-201. doi: 10.4155/fmc.09.163. Erratum in: Future Med Chem. 2011 Jan;3(1):138.

PMID:
21426186
15.

Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome.

Bagley MC, Davis T, Dix MC, Fusillo V, Pigeaux M, Rokicki MJ, Kipling D.

Future Med Chem. 2010 Sep;2(9):1417-27. doi: 10.4155/fmc.10.217.

PMID:
21426137
16.

Resveratrol, but not dihydroresveratrol, induces premature senescence in primary human fibroblasts.

Faragher RG, Burton DG, Majecha P, Fong NS, Davis T, Sheerin A, Ostler EL.

Age (Dordr). 2011 Dec;33(4):555-64. doi: 10.1007/s11357-010-9201-5. Epub 2011 Feb 12.

17.

Evaluating the role of p38 MAP kinase in growth of Werner syndrome fibroblasts.

Davis T, Bachler MA, Wyllie FS, Bagley MC, Kipling D.

Ann N Y Acad Sci. 2010 Jun;1197:45-8. doi: 10.1111/j.1749-6632.2010.05195.x. Review.

PMID:
20536832
18.

Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome.

Bagley MC, Davis T, Murziani PG, Widdowson CS, Kipling D.

Pharmaceuticals (Basel). 2010 Jun 4;3(6):1842-1872. Review.

19.

Microwave-assisted Ullmann C-S bond formation: synthesis of the P38alpha MAPK clinical candidate VX-745.

Bagley MC, Davis T, Dix MC, Fusillo V, Pigeaux M, Rokicki MJ, Kipling D.

J Org Chem. 2009 Nov 6;74(21):8336-42. doi: 10.1021/jo9017155.

PMID:
19778055
20.

Assessing the role of stress signalling via p38 MAP kinase in the premature senescence of ataxia telangiectasia and Werner syndrome fibroblasts.

Davis T, Kipling D.

Biogerontology. 2009 Jun;10(3):253-66. doi: 10.1007/s10522-008-9179-x. Epub 2008 Oct 1.

PMID:
18830681

Supplemental Content

Loading ...
Support Center